Media coverage
8
Media coverage
Title Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis Media name/outlet Business Wire Country/Territory United States Date 10/12/24 URL ct.moreover.com/?a=55512581046&p=1gw&v=1&x=fm_u3BCVVSY1jCktIY0u7g Persons John Mascarenhas Title Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO(TM) (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis Media name/outlet Business Wire Country/Territory United States Date 10/12/24 Persons John Mascarenhas Title Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis Media name/outlet ADVFN UK Country/Territory United Kingdom Date 10/12/24 URL ct.moreover.com/?a=55512533194&p=1gw&v=1&x=jN7Dsx8GzrMoVgCUA3XyxA Persons John Mascarenhas Title Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis Media name/outlet StockTitan.net Country/Territory United States Date 10/12/24 URL ct.moreover.com/?a=55512562217&p=1gw&v=1&x=j4zJjPE6cNY47kr1CkllcA Persons John Mascarenhas Title Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis Media name/outlet Yahoo! Finance Country/Territory United States Date 10/12/24 URL ct.moreover.com/?a=55512668635&p=1gw&v=1&x=jy3-Ml1du-YQAsOjXc7Fzw Persons John Mascarenhas Title Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELOtm (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis Media name/outlet Le Lezard.com Country/Territory Canada Date 10/12/24 URL ct.moreover.com/?a=55512618743&p=1gw&v=1&x=lxL6pXHYGguZRrDLRwUltA Persons John Mascarenhas Title Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO(TM) (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis Media name/outlet Stockwatch Country/Territory Canada Date 10/12/24 URL ct.moreover.com/?a=55512624433&p=1gw&v=1&x=3seYHHzeg3V_g0hQt5KzDQ Persons John Mascarenhas Title Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis Media name/outlet Crwe World Country/Territory United States Date 10/12/24 URL ct.moreover.com/?a=55512723936&p=1gw&v=1&x=GTxolq99-6IqZgb7lhVVSw Persons John Mascarenhas